Down-regulation of TM4SF is associated with the metastatic potential of gastric carcinoma TM4SF members in gastric carcinoma

World Journal of Surgical Oncology

Volumn 9, Issue , 2011, Pages

  Chen, Zhouxun ^a,b   Gu, Suchen ^b   Trojanowicz, Bogusz ^b   Liu, Naxin ^a   Zhu, Guanbao ^a   Dralle, Henning ^b   Hoang Vu, Cuong ^b  

^a THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD63 ANTIGEN; CD82 ANTIGEN; CD9 ANTIGEN; MEMBRANE PROTEIN; MESSENGER RNA; PROTEIN TM4SF; UNCLASSIFIED DRUG; CD82 PROTEIN, HUMAN; FIBRINOGEN RECEPTOR; LEUKOCYTE ANTIGEN;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; CARCINOGENESIS; CARCINOMA CELL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENDER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; STOMACH CARCINOMA; STOMACH EPITHELIUM; STOMACH ULCER; DOWN REGULATION; GENE EXPRESSION; GENETICS; PROGNOSIS; RETROSPECTIVE STUDY; STOMACH TUMOR;

ANTIGENS, CD; DOWN-REGULATION; GENE EXPRESSION; HUMANS; KANGAI-1 PROTEIN; MEMBRANE GLYCOPROTEINS; PLATELET MEMBRANE GLYCOPROTEINS; PROGNOSIS; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS;

EID: 79957882580     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-9-43     Document Type: Article

References (39)

1. Wright MD, Tomlinson MG. The ins and outs of the transmembrane 4 superfamily. Immunol Today 1994, 15:588-594. 10.1016/0167-5699(94)90222-4, 7531445.
2. Ikeyama S, Koyama M, Yamaoko M, Sasada R, Miyake M. Suppression of cell motility and metastasis by transfection with human motility-related protein (MRP-1/CD9) DNA. J Exp Med 1993, 177:1231-1237. 10.1084/jem.177.5.1231, 2191011, 8478605.
3. Dong JT, Suzuki H, Pin SS, et al. Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. Cancer Res 1996, 56:4387-4390.
4. Radford KJ, Thorne RF, Hersey P. CD63 associates with transmembrane 4 superfamily members, CD9 and CD81, and with beta1 integrins in human melanoma. Biochem Biophys Res Commun 1996, 222:13-18. 10.1006/bbrc.1996.0690, 8630057.
5. Maecker HT, Todd SC, Levy S. The tetraspanin superfamily: molecular facilitators. FASEB J 1997, 11(6):428-442.
6. Boucheix C, Rubinstein E. Tetraspanins. Cell Mol Life Sci 2001, 58(9):1189-1205. 10.1007/PL00000933, 11577978.
7. Miller WJ, Gonzalez-Sarmiento R, Kersey JH. Immunoglobulin and T-cell receptor gene rearrangement in blast crisis of chronic myelocytic leukemia. Exp Hematol 1988, 16(10):884-888.
8. Berditchevski F. Complexes of tetraspanins with integrins: more than meets the eye. J Cell Sci 2001, 114:4143-4151.
9. Berditchevski F, Odintsova E. Characterization of integrin-tetraspanin adhesion complexes: role of tetraspanins in integrin signaling. J Cell Biol 1999, 146:477-492. 10.1083/jcb.146.2.477, 2156181, 10427099.
10. Gutierrez-Lopez MD, Ovalle S, Yanez-Mo M, et al. A functionally relevant conformational epitope on the CD9 tetraspanin depends on the association with activated h1 integrin. J Biol Chem 2003, 278:208-218.
11. Longo N, Yáñez-Mó M, Mittelbrunn M, de la Rosa G, Muñoz ML, Sánchez-Madrid F, Sánchez-Mateos P. Regulatory role of tetraspanin CD9 in tumor-endothelial cell interaction during transendothelial invasion of melanoma cells. Blood 2001, 98:3717-3726. 10.1182/blood.V98.13.3717, 11739177.
12. Peñas PF, García-Díez A, Sánchez-Madrid F, Yáñez-Mó M. Tetraspanins are localized at motility-related structures and involved in normal human keratinocyte wound healing migration. J Invest Dermatol 2000, 114:1126-1135. 10.1046/j.1523-1747.2000.00998.x, 10844555.
13. Higashiyama M, Taki T, Ieki Y, et al. Reduced motility related protein-1 (MRP-1/CD9) gene expression as a factor of poor prognosis in non-small cell lung cancer. Cancer Res 1995, 55:6040-6044.
14. Huang CI, Kohno N, Ogawa E, Adachi M, Taki T, Miyake M. Correlation of reduction in MRP-1/CD9 and KAI1/CD82 expression with recurrences in breast cancer patients. Am J Pathol 1998, 153:973-983. 10.1016/S0002-9440(10)65639-8, 1853017, 9736046.
15. Mori M, Mimori K, Shiraishi T, Haraguchi M, Ueo H, Barnard GF, Akiyoshi T. Motility related protein 1 (MRP1/CD9) expression in colon cancer. Clin Cancer Res 1998, 4:1507-1510.
16. Dong JT, Lamb PW, Rinker-Schaeffer CW, Vukanovic J, Ichikawa T, Isaacs JT, Barrett JC. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science 1995, 268:884-886. 10.1126/science.7754374, 7754374.
17. Guo X, Friess H, Graber HU, Kashiwagi M, Zimmermann A, Korc M, Büchler MW. KAI1 expression is up-regulated in early pancreatic cancer and decreased in the presence of metastasis. Cancer Res 1996, 56:4876-4880.
18. Yu Y, Yang JL, Markovic B, Jackson P, Yardley G, Barrett J, Russell PJ. Loss of KAI1 messenger RNA in both high grade and invasive human bladder cancers. Clin Cancer Res 1997, 3:1045-1049.
19. Ow K, Delprado W, Fisher R, Barrett J, Yu Y, Jackson P, Russell PJ. Relationship between expression of the KAI1 metastasis suppressor and other markers of advanced bladder cancer. J Pathol 2000, 191:39-47. 10.1002/(SICI)1096-9896(200005)191:1<39::AID-PATH580>3.0.CO;2-K, 10767717.
20. Yang X, Wei L, Tang C, Slack R, Montgomery E, Lippman M. KAI1 Protein Is Down-Regulated during the Progression of Human Breast Cancer. Clin Cancer Res 2000, 6:3424-3429.
21. Hashida H, Takabayashi A, Tokuhara T, et al. Integrin alpha3 expression as a prognostic factor in colon cancer: association with MRP-1/CD9 and KAI1/CD82. Int J Cancer 2002, 97(4):518-525. 10.1002/ijc.1625, 11802216.
22. Lombardi DP, Geradts J, Foley JF, Chiao C, Lamb PW, Barrett JC. Loss of KAI1 expression in the progression of colorectal cancer. Cancer Res 1999, 59(22):5724-5731.
23. Uzawa K, Ono K, Suzuki H, et al. High Prevalence of Decreased Expression of KAI1 Metastasis Suppressor in Human Oral Carcinogenesis. Clin Cancer Res 2002, 828-835.
24. Radford KJ, Thorne RF, Hersey P. Regulation of tumor cell motility and migration by CD63 in a human melanoma cell line. J Immunol 1997, 158(7):3353-3358.
25. Radford KJ, Mallesch J, Hersey P. Suppression of human melanoma cell growth and metastasis by the melanoma-associated antigen CD63 (ME491). Int J Cancer 1995, 62(5):631-635. 10.1002/ijc.2910620523, 7665237.
26. Chen Z, Mustafa T, Trojanowicz B, et al. CD82 and CD63 in thyroid cancer. Int J Mol Med 2004, 14(4):517-27.
27. Miyake M, Nakano K, Itoi SI, Koh T, Taki T. Motility-related protein-1 (MRP-1/CD9) reduction as a factor of poor prognosis in breast cancer. Cancer Res 1996, 56:1244-1249.
28. Hotta H, Ross AH, Huebner K, et al. Molecular cloning and characterization of an antigen associated with early stage of melanoma tumor progression. Cancer Res 1988, 48:2955-2962.
29. Liu WM, Zhang XA. KAI1/CD82, a tumor metastasis suppressor. Cancer lett 2006, 240:183-194. 10.1016/j.canlet.2005.08.018, 16260083.
30. Friess H, Guo XZ, Berberat P, Graber HU, Zimmermann A, Korc M, Büchler MW. Reduced KAI1 expression in pancreatic cancer is associated with lymph node and distant metastases. Int J Cancer 1998, 79:349-355. 10.1002/(SICI)1097-0215(19980821)79:4<349::AID-IJC7>3.0.CO;2-V, 9699525.
31. Su JS, Arima K, Hasegawa M, et al. Decreased expression of KAI1 metastasis suppressor gene is a recurrence predictor in primary pTa and pT1 urothelial bladder carcinoma. Int J Urol 2004, 11:74-82. 10.1111/j.1442-2042.2004.00752.x, 14706010.
32. Bouras T, Rauman AG. Expression of the prostate cancer metastasis suppressor gene KAI1 in primary prostate cancers: a biphasic relationship with tumour grade. J Pathol 1999, 188:382-388. 10.1002/(SICI)1096-9896(199908)188:4<382::AID-PATH365>3.0.CO;2-O, 10440748.
33. Maurer CA, Graber HU, Friess H, et al. Reduced expression of the metastasis suppressor gene KAI1 in advanced colon cancer and its metastases. Surgery 1999, 126:869-880. 10.1016/S0039-6060(99)70028-0, 10568187.
34. Adachi M, Taki T, Ieki Y, Huang CL, Higashiyama M, Miyake M. Correlation of CD82 gene expression with good prognosis in patients with non-small cell lung cancer. Cancer Re 1996, 56:1751-1755.
35. Berditchevski F, Odintsova E. Characterization of integrin-tetraspanin adhesion complexes: role of tetraspanins in integrin signaling. J Cell Biol 1999, 146:477-492. 10.1083/jcb.146.2.477, 2156181, 10427099.
36. Hemler ME. Tetraspanin functions and associated microdomains. Nat Rev Mol Cell Biol 2005, 6(10):801-11. 10.1038/nrm1736, 16314869.
37. Gu J, Tamura M, Pankov R, Danen EH, Takino T, Matsumoto K, Yamada KM. Shc and FAK differentially regulate cell motility and directionality modulated by PTEN. J Cell Bio 1999, 146:386-403.
38. Kolesnikova TV, Stipp CS, Rao RM, Lane WS, Luscinskas FW, Hemler ME. EWI-2 modulates lymphocyte integrin a4β1fuctions. Blood 2004, 103:3013-3019. 10.1182/blood-2003-07-2201, 15070678.
39. Odintsova E, Sugiura T, Beditchevski F. Attenuation of EGF receptor signaling by a metastasis suppressor, the tetraspanin CD82/KAI-1. Curr Biol 2000, 10:1009-1012. 10.1016/S0960-9822(00)00652-7, 10985391.